Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimisation of Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg

NCT02698384 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT02698384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02698384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimisation of Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg
Lead sponsor
Ipsen
Phase
Observational
Overall status
Terminated
Start date
January 31, 2016
Completion date
June 30, 2016
Enrollment
4 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acromegaly